daraxonrasib

NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...

OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...

REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...

REDWOOD CITY, Calif., Sept. 2, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a commercial-stage oncology company focused on RAS-driven cancers,...

Research Triangle Park, North Carolina, August 31, 2026 Veloxis Pharmaceuticals, Inc. announced that the first patient has been dosed...

Indianapolis, Indiana, and Cambridge, Massachusetts, August 31, 2026 Eli Lilly and Company and Merida Biosciences, Inc. announced a definitive...

Detroit, Michigan, August 31, 2026 The Barbara Ann Karmanos Cancer Institute announced that it is now offering FDA-approved daraxonrasib...

South San Francisco, California – August 27, 2026 CytomX Therapeutics announced that the U.S. Food and Drug Administration (FDA)...

Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...

REDWOOD CITY, Calif., August 26, 2026 Revolution Medicines, Inc. has received U.S. Food and Drug Administration (FDA) approval for...